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1. Introduction 
In the past, the action of anaesthetics was generally 
interpreted in terms of rather unspecific hydrophobic 
interactions between drugs and biological structures 
(for a review see ref. [1 ] ). Recent results, however, 
suggest he existence of specific binding sites for 
compounds like xenon [2,3] and halothane [4,5]. 
The nature of halothane receptors might be elucidated 
by investigating the molecular basis of malignant 
hyperthermia [6]. This fatal syndrome which some 
individuals develop in response to halothane anaesthesi~ 
is characterized, among other findings, by muscle 
rigidity and a continuous rise of the body temper- 
ature. In several cases halothane-induced malignant 
hyperthermia was found to be associated with 
adenylate kinase (EC 2.7.4.3) deficiency [7]. Further- 
more, a direct effect of the anaesthetic on the 
structure and function of this enzyme, which catalyzes 
the reaction ATP + AMP. ~- 2ADP, was demonstrated 
by various methods [8-10]. 
These observations prompted us to investigate the 
binding of halothane to crystals of adenylate kinase 
by X-ray diffraction analysis. It was found that halo- 
thane does not bind to all accessible hydrophobic 
regions of the protein, but only to the niche which 
has been identified as the binding sit~ of the adenine 
moiety of AMP[ 11]. 
2. Materials and methods 
The substrates and the coupling enzymes used in 
the assay for adenylate kinase were obtained from 
Boehringer, Mannheim, halothane from Hoechst, 
Frankfurt and all other reagents from Merck, 
Darmstadt. 
For experimental reasons adenylate kinase from 
pig muscle was chosen which is almost identical with 
the human enzyme [12]. Moreover, malignant 
hyperthermia is common in pigs [13]. Crystals of 
adenylate kinase [14] were prepared as previously 
described [ 14,15]. In order to bind halothane the 
enzyme crystals were soaked at 4°C for 1-2 days, at 
pH 6.1, in 0.1 M Tris-maleate/3 M (NH4)2SO 4
saturated with halothane. 
X-Ray diffraction data of the crystals were 
collected to a resolution of 0.6 nm using a method 
described by Schulz et al. [15]. Because of crystal 
instability higher esolution could not be obtained. 
The location of halothane on the molecule was 
derived reproducibly from a difference-Fourier map 
[16] on the basis of the known protein structure 
[ 14]. Part of this map is shown in fig.1. 
In kinetic experiments he activity of adenylate 
kinase was measured at 25°C in a coupled enzyme 
assay determining the production of ADP [ 17,18]. 
A3 ml assay mixture, ofpH 6.5, contained 0.1 M 
Tris-maleate, 3 mM MgCI2, 350/aM phosphoenol- 
pyruvate, 180/aM NADH, 10 units pyruvate kinase, 
10 units lactate dehydrogenase and rate limiting 
amounts of human or porcine adenylate kinase. In 
all experiments in which the concentration f the 
substrate AMP was higher than 500/aM, 2.5 mM 
halothane had no effect on the enzyme activity; this 
was true for high (1 raM) and for low (20/~M) con- 
centrations of ATP. However, in the presence of 
100/aM AMP (and 1 mM ATP) 2.5 mM halothane 
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Fig. 1. Difference-Fourier map of adenylate kinase soaked 
with halothane minus adenylate kinase. The enzyme isin the 
B-conformation [ 14 ], space group P3121, crystal, axes 
a = b = 4.85 nm, c -- 13.9 nm. The map section isz = 8•60. 
Contours are drawn at 40%, 50%,.. 90% of maximum density 
in the map. Only the main peak is significantly above the 
noise level. Taking into account the density of the under- 
lying protein map, the atomic number difference between 
halothane and protein and the intrinsic reduction factor 0.5 
of a difference-Fourier [16], the width and height of the 
peak correspond tomore than 50% occupancy by halothane. 
caused 50% inhibition of adenylate kinase; this 
inhibitory effect could be reversed by evaporating 
the anaesthetic. 
3. Results and discussion 
The difference-Fourier map (adenylate kinase 
soaked with halothane minus adenylate kinase) 
contains one significant peak (fig. I). All other peaks 
of the map exceed the general noise level only slightly. 
The peak size is about 0.8 X 0.7 X 0.5 nm which 
corresponds roughly to the dimensions of a halo. 
thane molecule (BrC1CH-CF3) at 0.6 nm resolution. 
From the width and the height of the peak it was 
estimated that at least every second crystalline nzyme 
molecule contains aspecifically-bound halothane 
molecule. 
The halothane binding site is a hydrophobic pocket 
deep in the protein molecule. The location of this 
site with respect to the general chain fold is illustrated 
in fig.2. In earlier experiments [11], this pocket was 
identified as the binding of the adenine moiety of 
AMP. At the obtainable resolution o details of the 
interaction between halothane and protein side chains 
¢ 
N 
Fig.2. Sketch of adenylate kinase with a bound halothane 
molecule (hatched ellipsoid). The atomic structure of the 
enzyme isknown [24,25]. Strands of the central #-pleated 
sheet are represented byarrows and a-helices by cylinders. 
Halothane binds in a hydrophobic pocket which has been 
identified as the binding-site ofthe adenine moiety of the 
substrate AMP [ 11 ]. 
are perceptible; it is, however, known that the pocket 
is lined by the side chains of Cys-25 as well as Ile-I 1, 
Val-13, Set-19, Gly-20, Gln-24, Ile-28, Leu-91, Leu-116, 
Leu-118 and Val-186. 
As halothane occupies the position of the substrate 
AMP, the crystallographic results uggest that the 
anaesthetic affects the enzyme activity. This is in 
agreement with the findings of Schmidt and his 
collaborators [9,10] as well as with the kinetic 
experiments described above. Only when AMP was 
the variable substrate a reversible inhibitory effect 
ofhalothane on human and procine adenylate kinase 
was observed. 
The conditions used in vitro (2.5 mM halothane, 
100"/~M AMP, pH 6.5 etc) can be assumed to be in 
the same range as the corresponding conditions in the 
muscle cells of an anaesthesized person [19]. Con, 
sequently our results support Schmidt's hypothesis on 
the aetiology of halothane-induced malignant hyper- 
thermia [9,10]. According to Schmidt malignant 
hyperthermia ensues when inherited adenylate kinase 
deficiency is aggravated by the inhibitory effect of 
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halothane during anaesthesia. In the absence of suf- 
ficient adenylate kinase activity, the ratio of 
[ATP] : [ADP] : [AMP] in the cell cannot be 
regulated any longer [17] which is assumed to 
precipitate the observed sequence of metabolic 
derangements in malignant hyperthermia. It should 
be stressed that this fatal syndrome might not be 
associated with adenylate kinase deficiency in all 
cases; other aetiologies have been proposed as well 
[21-23] .  
4. Conclusion 
Adenylate kinase may serve as a model for biological 
structures in which a purine binding site is affected 
by halothane (fig.l). It is indeed remarkable that all 
proteins for which specific interactions with halothane 
have been demonstrated [19] process functionally 
important binding sites for purine nucleotides; 
examples are microtubules [20], glutamate dehydro- 
genase [4], calcium-transport ATPases [5,21,22] and 
phosphoryl transferases [10,23]. This aspect could 
facilitate the search for the principal halothane 
receptors in normal anaesthesia. 
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